HUTCHMED Reports the P-III Trial Data and will Highlight Hematological Malignancy Programs at the EHA 2024
Shots: HUTCHMED has reported the P-III (
Eli Lilly Reports Data from Two P-III (QWINT-2 and QWINT-4) Studies of Efsitora for Treating Type 2 Diabetes
Shots: The P-III (QWINT-2 & QWINT-4) studies assess the safety & efficacy...
Roche Reveals Results from the P-I Clinical Evaluation of CT-388 for Treating Obesity and Type 2 Diabetes
Shots: The P-I (CT-388-101) study assesses the safety, tolerability & PK/PD of...
Ocugen Concludes Dosing in Cohort 2 of the P-I/II Study Evaluating OCU410ST for Stargardt Disease
Shots: Ocugen has concluded the dosing in cohort 2 of the P-I/II (GARDian) study....
HUTCHMED Commences the P-II/III Study of Surufatinib Plus Camrelizumab for Pancreatic Ductal Adenocarcinoma
Shots: HUTCHMED has commenced the P-II/III study of its surufatinib (angio-immuno...
